By Rob Waters
Feb. 2 (Bloomberg) -- A blood-washing treatment may whisk Biogen Idec Inc.’s Tysabri from the bloodstreams of patients with multiple sclerosis, potentially neutralizing a rare side effect before it turns deadly.
Tysabri was pulled from the market in February 2005 by Biogen and its marketing partner, Elan Corp., after three patients developed a viral brain disease called progressive multifocal leukoencephalopathy, or PML, and two of them died.
Since U.S. regulators allowed the companies to resume selling the drug in July 2006, four new cases of the brain disease have been reported among Tysabri users. All four patients were treated with the blood-washing method and only one of them died, said Robert Fox, medical director of the Mellen Center for Multiple Sclerosis at the Cleveland Clinic. A study led by Fox, funded by Biogen, and published today in the journal Neurology showed that blood-washing reduced Tysabri to acceptable levels within two weeks.
“If you decide that a patient needs to get rid of the drug, you want to do it as fast as you can,” Fox said in a telephone interview today. “We were able to reduce Tysabri levels by 92 percent” with the treatment.
Tysabri, Biogen’s second-best-selling medicine, is approved to treat multiple sclerosis patients who aren’t helped by other drugs. Tysabri generated $597 million in sales in the first nine months of 2008, and sales growth slowed in the fourth quarter, Chief Executive Officer James Mullen told investors on Jan. 13 at the JPMorgan Healthcare Conference in San Francisco.
Purifying Plasma
The blood-washing method, known to doctors as plasmapheresis or plasma exchange, draws blood from a patient’s arm. Purified plasma, the liquid component of blood, is then returned to the other arm during a two- to three-hour process. In Fox’s study, 12 Tysabri users who didn’t have the brain disease had three blood- washing sessions to see if the approach could work. In all 12, Tysabri levels were lowered by an amount that Fox said may stop the progression of the brain illness if they had it.
Because Fox and his colleagues had presented early results from the study at medical meetings in 2007 and 2008, doctors used the technique on the four patients who developed the brain disease last year.
The technique could improve clinical outcomes for Tysabri patients who develop PML, said Shannon Altimari, a Biogen spokeswoman.
Medical consultants advising Leerink Swann & Co. said they believe the report “could make physicians more comfortable with prescribing Tysabri,” said William Tanner, a Leerink analyst, in a note to investors today. The decline in the number of new patients starting Tysabri may have stabilized, “perhaps providing an opportunity for regrowth in the next few quarters,” he said.
To contact the reporter on this story: Rob Waters in San Francisco at rwaters5@bloomberg.net.
Last Updated: February 2, 2009 18:02 ESTPosting comments can be beneficial to others and it allows you to express yourself.
If you have a statement or question pertaining to this article, this is the place to leave it.
Click the link below the article that reads: Post Comments. - Thank You
============================================
2 comments:
This statement made by Ron Waters in the article: "Tysabri, Biogen’s second-best-selling medicine, is approved to treat multiple sclerosis patients who aren’t helped by other drugs" is completely incorrect .
Tysabri is FDA approved for "relapsing forms" of MS, which include Relapsing Remitting, Progressive Relapsing & SPMS with Relapses.
Just to be clear,Tysabri can and has been used as a first line and a second line defense in treating MS, particularly in aggressive forms of MS.
Lauren
I did not write the article. Just posted what I found on the Bloomberg report. There is an email address found with the article where you can write to the journalist.
Post a Comment